Escient Pharmaceuticals, Inc.

14 articles with Escient Pharmaceuticals, Inc.

• Escient Pharmaceuticals Appoints Joshua Grass, MBA as CEO

  1/5/2022

  Escient Pharmaceuticals today announced the appointment of Joshua Grass, MBA as Chief Executive Officer effective immediately.

• 

  4 Companies Ringing in New Year with New CEOs

  1/5/2022

  Several biopharma companies have adjusted their leadership teams to include new chief executive officers who are expected to guide the companies and their programs into the future.

• Escient Pharmaceuticals Announces Data Presentations Highlighting the Preclinical and Clinical Development of EP547 at AASLD The Liver Meeting® Digital Experience 2021

  11/4/2021

  Escient Pharmaceuticals Announces Data Presentations Highlighting the Preclinical and Clinical Development of EP547 at AASLD The Liver Meeting ® Digital Experience 2021

• Escient Pharmaceuticals Announces Positive Results from Phase 1 Study of EP547, an MrgprX4-Targeted Oral Therapy for Cholestatic and Uremic Pruritus

  7/14/2021

  Escient Pharmaceuticals today announced positive results from a Phase 1 study of EP547, a new chemical entity and potent MrgprX4 antagonist, being developed for the treatment of pruritus associated with cholestasis and uremia.

• 

  BioSpace Movers & Shakers, May 28

  5/28/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Escient Pharmaceuticals Names Eric Deng, Ph.D., M.B.A. as Vice President, CMC Operations

  5/27/2021

  Escient Pharmaceuticals, Inc. , a clinical-stage, industry-leading platform company developing Mas-related G Protein-Coupled Receptor (MRGPR)-targeted drugs to address serious, unserved medical needs across a broad range of therapeutic indications, today announced that Eric Deng, Ph.D., M.B.A., has joined the company as Vice President, Chemistry, Manufacturing and Controls (CMC) Operations.

• 

  BioSpace Movers & Shakers, May 21

  5/21/2021

  Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers.

• Escient Pharmaceuticals Appoints Christian Weyer, M.D., M.A.S., as President and Chief Medical Officer

  5/17/2021

  Escient Pharmaceuticals, Inc. , a clinical-stage, industry-leading platform company developing Mas-related G Protein-Coupled Receptor (MRGPR)-targeted drugs to address serious, unserved medical needs across a broad range of therapeutic indications, today announced that Christian Weyer, M.D., M.A.S., has joined the company as President and Chief Medical Officer.

• 

  BioSpace Movers & Shakers, May 7

  5/7/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Escient Pharmaceuticals Names Svetlana Makhni as Chief Financial Officer

  5/3/2021

  Escient Pharmaceuticals, Inc., a clinical-stage, industry-leading platform company developing Mas-related G Protein-Coupled Receptor (MRGPR)-targeted drugs to address serious, unserved medical needs across a broad range of therapeutic indications, today announced the appointment of Svetlana Makhni as Chief Financial Officer effective May 3, 2021

• Escient Pharmaceuticals Raises $77.5 Million Series B Round and Initiates a Phase 1/1b Clinical Trial of EP547, a MRGPR-targeted Therapy to Treat Cholestatic and Uremic Pruritus

  9/14/2020

  Sept. 14, 2020 13:00 UTC -- Proceeds support clinical development for lead program in cholestatic and uremic pruritus and second program for mast cell-related diseases -- Financing round led by Sanofi Ventures and Cowen Healthcare Investments and included new investors Redmile Group and Perceptive Advisors -- Jason Hafler, Ph.D., of Sanofi Ventures and Kevin Raidy of Cowen Healthcare Investments join Escient board of directors SAN DIEGO--( BUSINESS WIRE )-- Es

• Eurofins Discovery Announces Collaboration with Escient Pharmaceuticals

  10/28/2019

  Eurofins Discovery provides premier, integrated drug discovery services for the pharma and biotech industry

• Escient Pharmaceuticals Announces Appointment of K. Peter Hirth to Board of Directors

  9/24/2019

  Escient Pharmaceuticals, Inc., a biotechnology company advancing first-in-class G Protein Coupled Receptor (GPCR)-targeted drugs to address unmet needs for a broad range of therapeutic indications, today announced the appointment of K. Peter Hirth to its Board of Directors

• Escient Pharmaceuticals Appoints Kristin Taylor, PhD as Vice President and Head of Clinical Development

  7/17/2019

  Seasoned industry leader to steer Escient’s clinical development and regulatory strategies as it advances first-in-class Mrgpr-focused pipeline